Receptos (UNKNOWN:RCPT.DL) shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec's (NASDAQ:BIIB) Avonex ongoing, there is some exciting data ahead too.
The phase 2 trial met its primary and secondary endpoints and showed what appeared to be a pretty clean safety profile. Of course, the big question is whether Receptos can compete effectively in a multiple sclerosis market littered with heavyweights like Biogen, Novartis (NYSE:NVS), and Teva (NYSE:TEVA).
In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss the trial results and why investors may want to wait for more data.
David Williamson owns shares of Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.